Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Aranesp Prescribers for Red Blood Cell Disorders (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 20, 2008
Electronic Records?? Great but.......
Analysis of: Most Doctors Aren’t Using Electronic Health Records | www.nytimes.com
Author: GLG Expert Contributor
Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)
June 19, 2008
GSK is going after Genentech's (Herceptin) Cookies....
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.
June 19, 2008
Melanoma: The Holy Grail at Last??
Analysis of: Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 | content.nejm.org
Author: GLG Expert Contributor
"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...
June 11, 2008
Targeted therapy for myeloproliferative disorders (MPD) from Cephalon
Analysis of: Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.
June 9, 2008
Diabetes: Let's avoid pseudoscience and start over.....
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Expert Contributor
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
June 4, 2008
Trovax(R) Sanofi-Aventis and Oxford Biomedica: Interesting but.....
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
June 4, 2008
ASA404 in a phase III trial in lung cancer?? "A crap shoot?"
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
June 2, 2008
A New Algorithm Will be Needed to Calculate Market Sharee
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
June 2, 2008
ImClone: One study shot down. The other??
Analysis of: Drug Brings ImClone in From Cold | online.wsj.com
Author: GLG Expert Contributor
Well we know that the lung cancer trial  http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await
June 2, 2008
Erbitux (ImClone):1 month and <10% additional survival in lung cancer. Not very impressive!
Analysis of: Erbitux Slightly Boosts Survival in Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 439

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T01:45:17.903